<< Back To Search

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is testing a new treatment for people with a type of cancer called Multiple Myeloma that has come back after treatment or didn't respond to treatment before. The treatment uses two new drugs called daratumumab and carfilzomib, along with two drugs that are commonly used called dexamethasone and pomalidomide.
*Third Opinion AI Generated Synopsis

Trial Summary
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. The names of the study drugs involved in this study are: Carfilzomib Daratumumab The names of the standard of care drugs involved in this study are: Dexamethasone Pomalidomide

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?